EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

被引：0
|
作者：
Van Gaal, Luc [1 ]
Garvey, Tim [1 ]
Leiter, Lawrence [1 ]
Vijapurkar, Ujjwala [1 ]
List, James [1 ]
Cuddihy, Robert [1 ]
Ren, Jimmy [1 ]
Davies, Michael [1 ]
机构：
[1] Janssen Sci Affairs LLC, Raritan, NJ USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(17)35061-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1222M-03
引用
收藏
页码：1672 / 1672
页数：1
相关论文
共 50 条
  • [1] Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes
    Van Gaal, L.
    Garvey, W. T.
    Leiter, L. A.
    Vijapurkar, U.
    List, J.
    Cuddihy, R.
    Ren, J.
    Davies, M. J.
    [J]. DIABETOLOGIA, 2017, 60 : S413 - S414
  • [2] Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
    Garvey, W. Timothy
    Van Gaal, Luc
    Leiter, Lawrence A.
    Vijapurkar, Ujjwala
    List, James
    Cuddihy, Robert
    Ren, Jimmy
    Davies, Michael J.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 85 : 32 - 37
  • [3] Achievement of glycaemic goals without hypoglycaemia with canagliflozin versus glimepiride in patients with type 2 diabetes
    Vercruysse, F.
    Davies, M. J.
    Merton, K.
    Vijapurkar, U.
    Simples, J.
    Carroll, A.
    Balis, D.
    [J]. DIABETOLOGIA, 2016, 59 : S339 - S340
  • [4] Effects of Rivoglitazone on Metabolic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus
    Truitt, Kenneth E.
    Moberly, James
    Schwocho, Lee
    Mun, Yong
    Chou, Hubert S.
    [J]. DIABETES, 2010, 59 : A182 - A182
  • [5] Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
    Watts, Nelson B.
    Bilezikian, John P.
    Usiskin, Keith
    Edwards, Robert
    Desai, Mehul
    Law, Gordon
    Meininger, Gary
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01): : 156 - 165
  • [6] Renal effects of canagliflozin in type 2 diabetes mellitus
    Perkovic, Vlado
    Jardine, Meg
    Vijapurkar, Ujjwala
    Meininger, Gary
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (12) : 2219 - 2231
  • [7] Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
    Triplitt, Curtis
    Cornell, Susan
    [J]. CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2015, 8 : 73 - 81
  • [8] Effects of pioglitzone and glimepiride on microvascular function in patients with diabetes mellitus type 2
    Forst, T
    Nguyen, M
    Langenfeld, M
    Friedrich, C
    Lübben, G
    Fennenkötter, U
    Kann, P
    Pfützner, A
    [J]. DIABETES, 2004, 53 : A308 - A308
  • [9] Effects of canagliflozin on biomarkers of cardiovascular stress in older patients with type 2 diabetes
    Sattar, N.
    Januzzi, J. L.
    Butler, J.
    Jarolim, P.
    Vijapurkar, U.
    Merton, K. W.
    Ren, J.
    Canovatchel, W.
    Desai, M.
    Davies, M. J.
    [J]. DIABETOLOGIA, 2017, 60 : S424 - S424
  • [10] Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Budoff, Matthew J.
    Wilding, John P. H.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
12345